
|Slideshows|May 23, 2018
Antibody Testing in Patients With Neurological and Psychiatric Symptoms
Author(s)Veronica Hackethal, MD
New research may help doctors determine when (and when not) to test for antiglutamate decarboxylase antibodies in patients with neurological disorders and psychiatric symptoms.
Advertisement
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease
2
Additional Insights From the U.S. POINTER Study at CTAD 2025: Heather M. Snyder, PhD
3
Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results
4
New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease
5


































